News
A federal judge rejected Novartis' request for a preliminary injunction to stop MSN Pharmaceuticals from selling a generic ...
8h
Investor's Business Daily on MSNNovartis Sacrifices A Breakout As One Of Its Bread-And-Butter Drugs MissesNovartis stock fell early Thursday after the drugmaker reported light sales of Cosentyx, one of its biggest moneymakers.
A federal judge in New Jersey denied a preliminary injunction sought by Novartis (NYSE:NVS) to block MSN Pharmaceuticals from launching a generic version of the former’s blockbuster heart failure ...
The pharmaceutical company raised its full-year profit guidance as ongoing demand for key drugs fueled growth in ...
CNBC's Karen Gilchrist weighs in on Novartis' second-quarter earnings and efforts to diversify its drug portfolio beyond its ...
Novartis could soon face generic competition for Entresto after judge's ruling.
Swiss pharmaceutical giant Novartis has raised its full-year earnings forecast, citing robust revenue growth from key ...
6don MSNOpinion
Novartis cannot block drugmaker MSN Pharmaceuticals from launching a generic version of its blockbuster heart-failure drug ...
3d
NDTV Profit on MSNDivi's Labs Shares Slide After Novartis' Entresto Loses Patent LawsuitDivi's Labs makes active pharmaceutical ingredients for Entresto for Novartis, which contributes nearly 8% to Hyderabad-based ...
12hon MSN
The latest Market Talks covering the Health Care sector. Published exclusively on Dow Jones Newswires at 4:20 ET, 12:20 ET ...
Novartis AG announced disappointing sales for a key psoriasis drug and the looming retirement of its respected finance chief, which overshadowed a modest outlook raise.
3d
Trade Brains on MSNPharma stock falls 4% after competitor acquires U.S. patent for heart failure medicineThe shares of one of India's leading API manufacturers, engaged in the production and export of APIs, intermediates, and ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results